Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H6Cl4O2S |
| Molecular Weight | 356.052 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(Cl)C=C(Cl)C=C1SC2=CC(Cl)=CC(Cl)=C2O
InChI
InChIKey=JFIOVJDNOJYLKP-UHFFFAOYSA-N
InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H
| Molecular Formula | C12H6Cl4O2S |
| Molecular Weight | 356.052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04813 | https://goo.gl/7Qnwi7 | https://www.ncbi.nlm.nih.gov/pubmed/26961873 | https://www.ncbi.nlm.nih.gov/pubmed/5567745 | https://www.ncbi.nlm.nih.gov/pubmed/23990907
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04813 | https://goo.gl/7Qnwi7 | https://www.ncbi.nlm.nih.gov/pubmed/26961873 | https://www.ncbi.nlm.nih.gov/pubmed/5567745 | https://www.ncbi.nlm.nih.gov/pubmed/23990907
Bithionol is a synthetic sulfanediyl-bis-dichlorphenol), potent photosensitizer with the potential to cause serious skin disorders, formerly marketed as an active ingredient in various topical drug products. Bithionol has antibacterial and anthelmintic properties along with algaecide activity. Bithionol has been shown to be a potent inhibitor of soluble adenylyl cyclase (sAC, Adenylate cyclase type 10 ), an intracellular enzyme important in the catalysis of ATP to cAMP. Bithionol is the first known sAC inhibitor to act through the bicarbonate binding site via a mostly allosteric mechanism. Bithionol is used for treatment of tapeworm infections of dogs, cats, and poultry and for tapeworm and rumen fluke infections of sheep, horses, cattle, and goats.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5854 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26961873 |
4.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Actamer Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % 1 times / day single, topical Studied dose Dose: 1 %, 1 times / day Route: topical Route: single Dose: 1 %, 1 times / day Sources: |
healthy, 22 years |
Other AEs: Contact dermatitis... |
2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
unhealthy, mean age 35 years Health Status: unhealthy Age Group: mean age 35 years Sex: M+F Sources: |
Other AEs: Abdominal pain aggravated... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Contact dermatitis | 1 % 1 times / day single, topical Studied dose Dose: 1 %, 1 times / day Route: topical Route: single Dose: 1 %, 1 times / day Sources: |
healthy, 22 years |
|
| Abdominal pain aggravated | 37.5% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
unhealthy, mean age 35 years Health Status: unhealthy Age Group: mean age 35 years Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| An improved thyroid hormone reporter assay to determine the thyroid hormone-like activity of amiodarone, bithionol, closantel and rafoxanide. | 2012-01-05 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Determination of bithionol, bromophen, nitroxynil, oxyclozanide, and tribromsalan in milk with liquid chromatography coupled with tandem mass spectrometry. | 2010-10-07 |
|
| In vitro toxicity of bithionol and bithionol sulphoxide to Neoparamoeba spp., the causative agent of amoebic gill disease (AGD). | 2010-09-17 |
|
| Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. | 2010-05-01 |
|
| A 20-year analysis of previous and emerging allergens that elicit photoallergic contact dermatitis. | 2010-04 |
|
| Endoscopic management of biliary fascioliasis: a case report. | 2010-03-06 |
|
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009-12-02 |
|
| Molecular cloning, expression and characterization of a novel mouse SULT6 cytosolic sulfotransferase. | 2009-09 |
|
| Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. | 2009-08-21 |
|
| Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. | 2009-07-14 |
|
| [Phosphatases of cestodes Bothriocephalus scorpii and influence of some anthelmintic preparations on activities of these enzymes]. | 2009-06-10 |
|
| Diphyllobothriasis associated with eating raw pacific salmon. | 2009-06 |
|
| Evaluation of marked rise in fecal egg output after bithionol administration to horse and its application as a diagnostic marker for equine Anoplocephala perfoliata infection. | 2009-05 |
|
| Further development of bithionol therapy as a treatment for amoebic gill disease in Atlantic salmon, Salmo salar L. | 2009-05 |
|
| Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis. | 2009-01-14 |
|
| The old and new therapeutic approaches to the treatment of giardiasis: where are we? | 2009 |
|
| In Vitro Anthelmintic Activity of Baliospermum montanum Muell. Arg roots. | 2008-01 |
|
| Treatment of helminth co-infection in individuals with HIV-1: A systematic review of the literature. | 2007-12-19 |
|
| An evaluation of the effects of photoactivation of bithionol, amiodarone and chlorpromazine on human keratinocytes in vitro. | 2007-10 |
|
| Evaluation of bithionol as a bath treatment for amoebic gill disease caused by Neoparamoeba spp. | 2007-03-31 |
|
| Slack and Slick K(Na) channels regulate the accuracy of timing of auditory neurons. | 2007-03-07 |
|
| Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA. | 2007-02 |
|
| Indirect evidence of ectopic pancreatic fascioliasis in a human. | 2006-10 |
|
| Pharmacological activation and inhibition of Slack (Slo2.2) channels. | 2006-09 |
|
| Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients. | 2006-03 |
|
| Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. | 2006-01-15 |
|
| Contractile activity and motility responses of the dog heartworm Dirofilaria immitis to classical anthelmintics and other compounds. | 2005-11-25 |
|
| Infection with Fasciola hepatica. | 2005-11 |
|
| Search of chemical scaffolds for novel antituberculosis agents. | 2005-04 |
|
| Acute toxicity to freshwater organisms of antiparasitic drugs for veterinary use. | 2005-02 |
|
| Fasciola hepatica infestation as a very rare cause of extrahepatic cholestasis. | 2004-10-15 |
|
| A native 13-kDa fatty acid binding protein from the liver fluke Fasciola hepatica. | 2004-09-24 |
|
| [Fascioliasis: diagnosis, epidemiology and treatment]. | 2004-05-07 |
|
| Sonographic findings of hepatic lesions in human fascioliasis. | 2003-09 |
|
| Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules. | 2003-03 |
|
| [Antiparasitic treatments in pregnant women and in children in 2003]. | 2003 |
|
| Paragonimiasis in Yongjia County, Zhejiang Province, China: clinical, parasitological and karyotypic studies on Paragonimus westermani. | 2001-12 |
|
| [Fasciola hepatica. study of a series of 37 patients]. | 2001-10 |
|
| Hydrogen peroxide induced stress in human keratinocytes and its effect on bithionol toxicity. | 2001-09-22 |
|
| Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. | 1996-12 |
|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Bithionol is given orally at a dose of 30 to 50 mg per kg of body weight on alternate days for ten to fifteen doses for the treatment of fascioliasis and paragonimiasis in adults and children.
After oral administration of single bithionol doses of 30 mg/kg body weight to
healthy test persons (fasting, number not stated) no effects were observed, single oral doses of 50 mg/kg body weight caused diarrhoea and 150 mg/kg body weight prolonged diarrhoea, nausea and abdominal pains
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24495391
Cytotoxic effect of BT (Bithionol) was evaluated against a panel of ovarian cancer cell lines (A2780 & A2780-CDDP OVACAR-3, SKOV-3, IGROV-1, and IGROV-1CDDP). A 20 mM stock of BT was prepared in DMSO and all the working dilutions were prepared in DMEM media. Ovarian cancer cell lines (5 × 103 cells/well) were plated into 96-well flat bottom plates (Corning, Inc., Corning, NY) and incubated for overnight. Cells were treated with different concentrations of BT ranging from 0.178 μM to 400 μM and further incubated for 48 hrs or 72 hrs. At least 4–6 hrs before the end of treatment time, presto blue reagent was added and incubated for total of 48 or 72 hrs and fluorescence measured (540 nm excitation/590 nm emissions). DMSO concentration was corrected to 1% in all wells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:42 GMT 2025
by
admin
on
Mon Mar 31 17:34:42 GMT 2025
|
| Record UNII |
AMT77LS62O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 216.24
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
WHO-ATC |
P02BX01
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
WHO-VATC |
QD10AB01
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
EPA PESTICIDE CODE |
64201
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
CFR |
21 CFR 700.11
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
WHO-ATC |
D10AB01
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
||
|
WHO-VATC |
QP52AG07
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C77030
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
SUB05857MIG
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
DB04813
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
202-565-0
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
m2577
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | Merck Index | ||
|
201
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
D001735
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
AMT77LS62O
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
6380
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
DTXSID9021342
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
97-18-7
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
100000086322
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
CHEMBL290106
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
BITHIONOL
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
3032
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
bithionol
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
47129
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
2406
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY | |||
|
3131
Created by
admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |